Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
240 results
Cited 6 times since 2023 (5.6 per year) source: EuropePMC
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Volume 25, Issue 4, 1 1 2023, Pages 1284-1295 STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe. Grehn M, Mandija S, Miszczyk M, Krug D, Tomasik B, Stickney KE, Alcantara P, Alongi F, Anselmino M, Aranda RS, Balgobind BV, Boda-Heggemann J, Boldt LH, Bottoni N, Cvek J, Elicin O, De Ferrari GM, Hassink RJ, Hazelaar C, Hindricks G, Hurkmans C, Iotti C, Jadczyk T, Jiravsky O, Jumeau R, Kristiansen SB, Levis M, López MA, Martí-Almor J, Mehrhof F, Møller DS, Molon G, Ouss A, Peichl P, Plasek J, Postema PG, Quesada A, Reichlin T, Rordorf R, Rudic B, Saguner AM, Ter Bekke RMA, Torrecilla JL, Troost EGC, Vitolo V, Andratschke N, Zeppenfeld K, Blamek S, Fast M, de Panfilis L, Blanck O, Pruvot E, Verhoeff JJC
The EU Horizon 2020 Framework-funded Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary (STOPSTORM) consortium has been established as a large research network for investigating STereotactic Arrhythmia Radioablation (STAR) for ventricular tachycardia (VT). The aim is to provide a pooled treatment database to evaluate patterns of practice and outcomes of STAR and finally to harmonize STAR within Europe. The consortium comprises 31... Abstract
Cited 9 times since 2023 (8.4 per year) source: EuropePMC
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Volume 25, Issue 4, 1 1 2023, Pages 1277-1283 Contemporary management of ventricular electrical storm in Europe: results of a European Heart Rhythm Association Survey. Baldi E, Conte G, Zeppenfeld K, Lenarczyk R, Guerra JM, Farkowski MM, de Asmundis C, Boveda S
Electrical storm (ES) is a predictor of mortality, and its treatment is challenging. Moreover, not all potential therapeutic strategies are available in all hospitals, and a standardized approach among European centres is lacking. The aim of this European Heart Rhythm Association (EHRA) survey was to assess the current management of patients with ES both in the acute and post-acute phases in 102 different European centres. A 20-item online questionnaire was sent out to the EHRA Research Network... Abstract
Cited 2 times since 2023 (1.7 per year) source: EuropePMC
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Volume 25, Issue 3, 1 1 2023, Pages 1035-1040 Unipolar voltage mapping in right ventricular cardiomyopathy: pitfalls, solutions and advantages. Hoogendoorn JC, Venlet J, de Riva M, Wijnmaalen AP, Piers SRD, Zeppenfeld K
Aims: Endocardial unipolar and bipolar voltage mapping (UVM/BVM) of the right ventricle (RV) are used for transmural substrate delineation. However, far-field electrograms (EGMs) and EGM changes due to injury current may influence automatically generated UVM. Epicardial BVM is considered less accurate due to the impact of fat thickness (FT). Data on epicardial UVM are sparse. The aim of the study is two-fold: to assess the influence of the manually corrected window-of-interest on UVM and the pot... Abstract
Cited 6 times since 2023 (5.1 per year) source: EuropePMC
JACC. Clinical electrophysiology, Volume 9, Issue 5, 22 4 2023, Pages 715-728 Management of Ventricular Arrhythmias Worldwide: Comparison of the Latest ESC, AHA/ACC/HRS, and CCS/CHRS Guidelines. Könemann H, Ellermann C, Zeppenfeld K, Eckardt L
A new guideline for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death has been published by the European Society of Cardiology (ESC). Beside the 2017 American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) guideline and the 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society (CCS/CHRS) position statement, this guideline provides evidence-based recommendations for clinical practice. As these recom... Abstract
Cited 8 times since 2023 (6.5 per year) source: EuropePMC
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Volume 25, Issue 1, 1 1 2023, Pages 199-210 European Society of Cardiology quality indicators for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Aktaa S, Tzeis S, Gale CP, Ackerman MJ, Arbelo E, Behr ER, Crotti L, d'Avila A, de Chillou C, Deneke T, Figueiredo M, Friede T, Leclercq C, Merino JL, Semsarian C, Verstrael A, Zeppenfeld K, Tfelt-Hansen J, Reichlin T
To develop a suite of quality indicators (QIs) for the management of patients with ventricular arrhythmias (VA) and the prevention of sudden cardiac death (SCD). The Working Group comprised experts in heart rhythm management including Task Force members of the 2022 European Society of Cardiology (ESC) Clinical Practice Guidelines for the management of patients with VA and the prevention of SCD, members of the European Heart Rhythm Association, international experts, and a patient representative.... Abstract
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Volume 25, Issue 2, 1 1 2023, Pages 478-486 The transmural activation interval: a new mapping tool to identify ventricular tachycardia substrates in right ventricular cardiomyopathy. Venlet J, Piers SR, Hoogendoorn J, Androulakis AFA, de Riva M, van der Geest RJ, Zeppenfeld K
Aims: In right ventricular cardiomyopathy (RVCM), intramural scar may prevent rapid transmural activation, which may facilitate subepicardial ventricular tachycardia (VT) circuits. A critical transmural activation delay determined during sinus rhythm (SR) may identify VT substrates in RVCM. Methods and results: Consecutive patients with RVCM who underwent detailed endocardial-epicardial mapping and ablation for scar-related VT were enrolled. The transmural activation interval (TAI, first endocar... Abstract
Cited 1 times since 2023 (0.8 per year) source: EuropePMC
JACC. Clinical electrophysiology, Volume 9, Issue 7 Pt 1, 18 3 2023, Pages 965-975 Volume-Weighted Unipolar Voltage Predicts Heart Failure Mortality in Patients With Dilated Cardiomyopathy and Ventricular Arrhythmias. Kimura Y, Beukers HKC, Rademaker R, Chen HS, Ebert M, Jensen T, Piers SR, Wijnmaalen AP, de Riva M, Dekkers OM, Stevenson WG, Zeppenfeld K
Background: Patients with dilated cardiomyopathy (DCM) who are undergoing catheter ablation of ventricular arrhythmias (VAs) are at risk of rapidly progressive heart failure (HF). Endocardial voltages decrease with loss of viable myocardium. Global left ventricular (LV) voltage as a surrogate for the amount of remaining viable myocardium may predict prognosis. Objectives: This study evaluated whether the newly proposed parameter volume-weighted (vw) unipolar voltage (UV) can predict HF-related a... Abstract
Cited 1 times since 2023 (0.8 per year) source: EuropePMC
JACC. Clinical electrophysiology, Volume 9, Issue 6, 18 3 2023, Pages 740-748 Head-to-Head Comparison of T1 Mapping and Electroanatomical Voltage Mapping in Patients With Ventricular Arrhythmias. Sramko M, Abdel-Kafi S, Wijnmaalen AP, Tao Q, van der Geest RJ, Lamb HJ, Zeppenfeld K
Background: Electroanatomical voltage mapping (EAVM) has been compared with late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR), which cannot delineate diffuse fibrosis. T1-mapping CMR overcomes the limitations of LGE-CMR, but it has not been directly compared against EAVM. Objectives: This study aims to assess the relationship between left ventricular (LV) endocardial voltage obtained by EAVM and extracellular volume (ECV) obtained by T1 mapping. Methods: The study investiga... Abstract
Circulation. Arrhythmia and electrophysiology, Volume 16, Issue 1, 3 1 2023, Pages e010826 Pleomorphic Ventricular Tachycardia in Dilated Cardiomyopathy Predicts Ventricular Tachycardia Recurrence After Ablation Independent From Cardiac Function: Comparison With Patients With Ischemic Heart Disease. Kimura Y, de Riva M, Ebert M, Glashan C, Wijnmaalen AP, Piers SR, Dekkers OM, Trines SA, Zeppenfeld K
Background: In dilated cardiomyopathy (DCM), outcome after catheter ablation of ventricular tachycardia (VT) is modest, compared with ischemic heart disease (IHD). Pleomorphic VT (PL-VT) has been associated with fibrotic remodeling and end-stage heart failure in IHD. The prognostic role of PL-VT in DCM is unknown. Methods: Consecutive IHD (2009-2016) or DCM (2008-2018) patients undergoing ablation for monomorphic VT were included. PL-VT was defined as ≥1 spontaneous change of the 12-lead VT-morp... Abstract
Cited 16 times since 2023 (12.1 per year) source: EuropePMC
European heart journal, Volume 44, Issue 3, 1 1 2023, Pages 176-177 The '10 commandments' for the 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Tfelt-Hansen J, Winkel BG, de Riva M, Zeppenfeld K
Cited 1 times since 2022 (0.7 per year) source: EuropePMC
Herz, Volume 48, Issue 1, 28 4 2022, Pages 3-14 [The new ESC guidelines on the management of ventricular tachyarrhythmias : Implications for daily practice]. Könemann H, Frommeyer G, Zeppenfeld K, Eckardt L
The recently published guidelines of the European Society of Cardiology (ESC) on the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death is an update of the 2015 guideline. For the first time a new section is dedicated to public basic life support. In the acute treatment of ventricular arrhythmias electrical cardioversion is upgraded, and there is a new focus on the management of electrical storm. Recommendations for the comprehensive diagnostic evaluat... Abstract
Cited 7 times since 2022 (4.7 per year) source: EuropePMC
Circulation. Arrhythmia and electrophysiology, Volume 15, Issue 11, 31 5 2022, Pages e011207 Longitudinal Prediction of Ventricular Arrhythmic Risk in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. Carrick RT, Te Riele ASJM, Gasperetti A, Bosman L, Muller SA, Pendleton C, Tichnell C, Murray B, Yap SC, van den Berg MP, Wilde A, Zeppenfeld K, Hays A, Zimmerman SL, Tandri H, Cadrin-Tourigny J, van Tintelen P, Calkins H, James CA, Wu KC
Background: The arrhythmogenic right ventricular cardiomyopathy (ARVC) risk calculator stratifies risk for incident sustained ventricular arrhythmias (VA) at the time of ARVC diagnosis. However, included risk factors change over time, and how well the ARVC risk calculator performs at follow-up is unknown. Methods: This was a retrospective analysis of patients with definite ARVC and without prior sustained VA. Risk factors for VA including age, nonsustained ventricular tachycardia, premature vent... Abstract
Cardiac electrophysiology clinics, Volume 14, Issue 4, 28 4 2022, Pages 709-727 Ventricular Tachycardia Ablation in Adult Congenital Heart Disease. Wallet J, Kimura Y, Zeppenfeld K
Patients with congenital heart disease (CHD) are at risk for late ventricular tachycardia (VT) and sudden cardiac death. Slow conducting anatomical isthmuses, bordered by unexcitable tissue created by valve annuli, ventricular incisions, and prosthetic material are the dominant substrate for macroreentrant monomorphic VTs in repaired CHD. These well-defined substrates allow for catheter or surgical transection with clear endpoints. This review elaborates on VT substrates in various CHD, and evol... Abstract
Cited 11 times since 2022 (7.2 per year) source: EuropePMC
Circulation. Arrhythmia and electrophysiology, Volume 15, Issue 11, 20 3 2022, Pages e000084 Arrhythmias in Repaired Tetralogy of Fallot: A Scientific Statement From the American Heart Association. Krieger EV, Zeppenfeld K, DeWitt ES, Duarte VE, Egbe AC, Haeffele C, Lin KY, Robinson MR, Sillman C, Upadhyay S, American Heart Association Adults With Congenital Heart Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young and Council on Clinical Cardiology
Arrhythmia and sudden cardiac death remain common in repaired tetralogy of Fallot and affect even those with excellent anatomic repairs. Atrial arrhythmia often has mechanisms different from those in acquired heart disease. Ventricular arrhythmia remains a major source of mortality in repaired tetralogy of Fallot. Noninvasive risk stratification is important to identify patients who may benefit from ablation or primary prevention implantable cardioverter defibrillators. Multiple noninvasive risk... Abstract
Cited 4 times since 2022 (2.6 per year) source: EuropePMC
Circulation, Volume 146, Issue 19, 7 1 2022, Pages 1434-1443 Programmed Ventricular Stimulation as an Additional Primary Prevention Risk Stratification Tool in Arrhythmogenic Right Ventricular Cardiomyopathy: A Multinational Study. Gasperetti A, Carrick RT, Costa S, Compagnucci P, Bosman LP, Chivulescu M, Tichnell C, Murray B, Tandri H, Tadros R, Rivard L, van den Berg MP, Zeppenfeld K, Wilde AAM, Pompilio G, Carbucicchio C, Dello Russo A, Casella M, Svensson A, Brunckhorst CB, van Tintelen JP, Platonov PG, Haugaa KH, Duru F, Te Riele ASJM, Khairy P, Tondo C, Calkins H, James CA, Saguner AM, Cadrin-Tourigny J
Background: A novel risk calculator based on clinical characteristics and noninvasive tests that predicts the onset of clinical sustained ventricular arrhythmias (VA) in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) has been proposed and validated by recent studies. It remains unknown whether programmed ventricular stimulation (PVS) provides additional prognostic value. Methods: All patients with a definite ARVC diagnosis, no history of sustained VAs at diagnosis, and PVS... Abstract
Cited 396 times since 2022 (252.2 per year) source: EuropePMC
European heart journal, Volume 43, Issue 40, 1 1 2022, Pages 3997-4126 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, Charron P, Corrado D, Dagres N, de Chillou C, Eckardt L, Friede T, Haugaa KH, Hocini M, Lambiase PD, Marijon E, Merino JL, Peichl P, Priori SG, Reichlin T, Schulz-Menger J, Sticherling C, Tzeis S, Verstrael A, Volterrani M, ESC Scientific Document Group
Cited 1 times since 2022 (0.6 per year) source: EuropePMC
JACC. Clinical electrophysiology, Volume 8, Issue 10, 28 4 2022, Pages 1234-1245 Ventricular Arrhythmia Substrate Distribution and Its Relation to Sympathetic Innervation in Nonischemic Cardiomyopathy Patients. Chen HS, Jungen C, Kimura Y, Dibbets-Schneider P, Piers SR, Androulakis AFA, van der Geest RJ, de Geus-Oei LF, Scholte AJHA, Lamb HJ, Jongbloed MRM, Zeppenfeld K
Background: Nonischemic cardiomyopathy patients referred for catheter ablation of ventricular arrhythmias (VAs) typically have either inferolateral (ILS) or anteroseptal (ASS) VA substrate locations, with poorer outcomes for ASS. Sympathetic denervation is an important determinant of arrhythmogenicity. Its relation to nonischemic fibrosis in general and to the different VA substrates is unknown. Objectives: This study sought to evaluate the association between VA substrates, myocardial fibrosis,... Abstract
Cited 8 times since 2022 (4.8 per year) source: EuropePMC
Journal of the American College of Cardiology, Volume 80, Issue 11, 1 1 2022, Pages 1045-1056 Clinical Outcomes in Patients With Dilated Cardiomyopathy and Ventricular Tachycardia. Zeppenfeld K, Wijnmaalen AP, Ebert M, Baldinger SH, Berruezo A, Catto V, Vaseghi M, Arya A, Kumar S, de Riva M, Deneke T, Gaspar T, Soejima K, van Rein N, Tedrow UB, Piorkowski C, Shivkumar K, Carbucicchio C, Hindricks G, Stevenson WG
Background: Recurrent ventricular tachycardia (VT) due to dilated cardiomyopathy (DCM) is difficult to treat, and long-term outcome data are limited. Objectives: The aim of this study was to identify predictors of mortality or heart transplantation (HTx) and VT recurrence. Methods: Consecutive patients with DCM accepted for radiofrequency catheter ablation (RFCA) of VT at 9 centers were prospectively enrolled and followed. Results: Of 281 consecutive patients (mean age 60 ± 13 years, 85% men, me... Abstract
Cited 19 times since 2022 (10.9 per year) source: EuropePMC
European heart journal, Volume 43, Issue 32, 1 1 2022, Pages e1-e9 A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Cadrin-Tourigny J, Bosman LP, Nozza A, Wang W, Tadros R, Bhonsale A, Bourfiss M, Fortier A, Lie ØH, Saguner AM, Svensson A, Andorin A, Tichnell C, Murray B, Zeppenfeld K, van den Berg MP, Asselbergs FW, Wilde AAM, Krahn AD, Talajic M, Rivard L, Chelko S, Zimmerman SL, Kamel IR, Crosson JE, Judge DP, Yap SC, van der Heijden JF, Tandri H, Jongbloed JDH, Guertin MC, van Tintelen JP, Platonov PG, Duru F, Haugaa KH, Khairy P, Hauer RNW, Calkins H, Te Riele ASJM, James CA
Aims: Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC) is characterized by ventricular arrhythmias (VAs) and sudden cardiac death (SCD). We aimed to develop a model for individualized prediction of incident VA/SCD in ARVC patients. Methods and results: Five hundred and twenty-eight patients with a definite diagnosis and no history of sustained VAs/SCD at baseline, aged 38.2 ± 15.5 years, 44.7% male, were enrolled from five registries in North America and Europe. Over 4.83 (interq... Abstract
Cited 5 times since 2022 (2.7 per year) source: EuropePMC
Cardiovascular research, Volume 118, Issue 10, 1 1 2022, Pages 2293-2303 Optical ventricular cardioversion by local optogenetic targeting and LED implantation in a cardiomyopathic rat model. Nyns ECA, Jin T, Fontes MS, van den Heuvel T, Portero V, Ramsey C, Bart CI, Zeppenfeld K, Schalij MJ, van Brakel TJ, Ramkisoensing AA, Zhang G, Poelma RH, Ördög B, de Vries AAF, Pijnappels DA
Aims: Ventricular tachyarrhythmias (VTs) are common in the pathologically remodelled heart. These arrhythmias can be lethal, necessitating acute treatment like electrical cardioversion to restore normal rhythm. Recently, it has been proposed that cardioversion may also be realized via optically controlled generation of bioelectricity by the arrhythmic heart itself through optogenetics and therefore without the need of traumatizing high-voltage shocks. However, crucial mechanistic and translation... Abstract